Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy and Amlodipine Monotherapy in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus

Authors

  • Raymond R. Townsend MD,

    1. From the University of Pennsylvania Medical Center, Philadelphia, PA ; 1St Luke’s Lipid and Diabetes Research Center, Kansas City, MO ; 2Novartis Healthcare Pvt Ltd, Madhapur, Hyderabad, India ; 3 and Novartis Pharmaceuticals Corporation, East Hanover, NJ4
    Search for more papers by this author
  • 1 Alan D. Forker MD, MACP,

    1. From the University of Pennsylvania Medical Center, Philadelphia, PA ; 1St Luke’s Lipid and Diabetes Research Center, Kansas City, MO ; 2Novartis Healthcare Pvt Ltd, Madhapur, Hyderabad, India ; 3 and Novartis Pharmaceuticals Corporation, East Hanover, NJ4
    Search for more papers by this author
  • 2 Vaishali Bhosekar MSc,

    1. From the University of Pennsylvania Medical Center, Philadelphia, PA ; 1St Luke’s Lipid and Diabetes Research Center, Kansas City, MO ; 2Novartis Healthcare Pvt Ltd, Madhapur, Hyderabad, India ; 3 and Novartis Pharmaceuticals Corporation, East Hanover, NJ4
    Search for more papers by this author
  • 3 Anthony Yadao MD,

    1. From the University of Pennsylvania Medical Center, Philadelphia, PA ; 1St Luke’s Lipid and Diabetes Research Center, Kansas City, MO ; 2Novartis Healthcare Pvt Ltd, Madhapur, Hyderabad, India ; 3 and Novartis Pharmaceuticals Corporation, East Hanover, NJ4
    Search for more papers by this author
  • and 4 Deborah L. Keefe MD, MPh 4

    1. From the University of Pennsylvania Medical Center, Philadelphia, PA ; 1St Luke’s Lipid and Diabetes Research Center, Kansas City, MO ; 2Novartis Healthcare Pvt Ltd, Madhapur, Hyderabad, India ; 3 and Novartis Pharmaceuticals Corporation, East Hanover, NJ4
    Search for more papers by this author

Author for correspondence: Raymond R. Townsend, MD, University of Pennsylvania, One Founders, 3400 Spruce Street, Philadelphia, PA 19104
E-mail: townsend@mail.med.upenn.edu

Abstract

J Clin Hypertens (Greenwich). 2011;13:889–897. ©2011 Wiley Periodicals, Inc.

Patients with stage 2 hypertension and diabetes are at high cardiovascular risk and require large blood pressure (BP) reductions to reach treatment goals. This randomized double-blind study compared aliskiren/hydrochlorothiazide (HCTZ) combination therapy with amlodipine monotherapy in 860 patients with mean sitting systolic BP (msSBP) ≥160 mm Hg to <200 mm Hg and type 2 diabetes. Patients received either once-daily aliskiren/HCTZ 150/12.5 mg or amlodipine 5 mg for 1 week then force-titrated to double the doses for 7 weeks. Baseline BP was 167.7/91.4 mm Hg. At week 8 end point, aliskiren/HCTZ provided significantly greater reductions in msSBP than amlodipine (28.8 mm Hg vs 26.2 mm Hg; P<.05). Mean sitting diastolic BP reductions were similar with aliskiren/HCTZ (9.9 mm Hg) and amlodipine (9.0 mm Hg). Achievement of BP control (<130/80 mm Hg) was significantly greater with aliskiren/HCTZ (23.2%) than amlodipine (13.8%; P<.0001). Aliskiren/HCTZ provides substantial msSBP reductions and greater BP control rates than amlodipine, and offers an attractive treatment option for patients with hypertension and diabetes mellitus. J Clin Hypertens (Greenwich). 2011;00:00–00. ©2011 Wiley Periodicals, Inc.

Ancillary